Over the past 12 months, 7 insiders at Pacira BioSciences, Inc. filed 15 open-market SEC Form 4 transactions on PCRX: 0 purchases worth $0 and 15 sales worth $2.3M. Insiders have been net sellers over this period. The most recent filing was on Apr 23, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 23, 26 | Shawn CrossChief Financial Officer | SELL | 12.9K | $25.16 | $326K |
| Apr 22, 26 | Shawn CrossChief Financial Officer | SELL | 1.5K | $25.01 | $38K |
| Apr 21, 26 | Shawn CrossChief Financial Officer | SELL | 2.8K | $25.01 | $71K |
| Apr 20, 26 | Shawn CrossChief Financial Officer | SELL | 7.7K | $25.14 | $194K |
| Mar 17, 26 | Mark FroimsonDirector | SELL | 500 | $21.81 | $11K |
| Mar 17, 26 | Jonathan SloninChief Medical Officer | SELL | 3.3K | $22.82 | $74K |
| Feb 2, 26 | Lauren RikerSenior Vice President, Finance | SELL | 4.0K | $20.81 | $83K |
| Feb 2, 26 | Kristen WilliamsChief Administrative Officer | SELL | 13.1K | $20.53 | $270K |
| Jan 5, 26 | Lauren RikerSenior Vice President, Finance | SELL | 1.4K | $24.24 | $34K |
| Dec 10, 25 | Shawn CrossChief Financial Officer | SELL | 9.1K | $25.14 | $229K |
| Dec 9, 25 | Shawn CrossChief Financial Officer | SELL | 15.9K | $25.03 | $398K |
| Nov 17, 25 | Jonathan SloninChief Medical Officer | SELL | 4.0K | $24.09 | $95K |
| Nov 10, 25 | Shawn CrossChief Financial Officer | SELL | 12.1K | $22.09 | $266K |
| Sep 4, 25 | Abraham CeesayDirector | SELL | 2.4K | $27.19 | $64K |
| Aug 7, 25 | Marcelo BigalDirector | SELL | 4.9K | $23.67 | $116K |
| Jun 4, 25 | Lauren RikerSenior Vice President, Finance | SELL | 5.6K | $26.21 | $146K |
| Jun 4, 25 | Kristen WilliamsChief Administrative Officer | SELL | 14.4K | $26.24 | $377K |
| Jan 6, 25 | Jonathan SloninChief Medical Officer | SELL | 879 | $18.40 | $16K |
| Dec 13, 24 | Daryl GauglerChief Operating Officer | SELL | 500 | $19.76 | $10K |
| Sep 13, 24 | Daryl GauglerChief Operating Officer | SELL | 500 | $12.86 | $6K |
| Aug 16, 24 | Marcelo BigalDirector | BUY | 1.5K | $13.25 | $20K |
| Aug 16, 24 | Laura BregeDirector | BUY | 1.0K | $12.81 | $13K |
| Aug 14, 24 | Michael J. YangDirector | BUY | 2.0K | $12.90 | $26K |
| Aug 12, 24 | Marcelo BigalDirector | BUY | 3.4K | $12.01 | $41K |
| Aug 12, 24 | Mark FroimsonDirector | BUY | 1.4K | $11.58 | $16K |
| Aug 12, 24 | Frank D. LeeChief Executive Officer | BUY | 8.3K | $12.10 | $100K |
| Aug 2, 24 | Jonathan SloninChief Medical Officer | SELL | 945 | $20.05 | $19K |
| Jul 2, 24 | Jonathan SloninChief Medical Officer | SELL | 2.8K | $28.25 | $80K |
| Jun 13, 24 | Daryl GauglerChief Operating Officer | SELL | 1.0K | $28.38 | $28K |
| Jun 13, 24 | Paul J HastingsDirector | SELL | 880 | $28.38 | $25K |
| Jun 13, 24 | Kristen WilliamsChief Administrative Officer | SELL | 7.5K | $28.38 | $211K |
| Jun 12, 24 | Lauren RikerSenior Vice President, Finance | SELL | 4.0K | $28.72 | $114K |
| Jun 11, 24 | Jonathan SloninChief Medical Officer | SELL | 5.0K | $28.57 | $143K |
| Mar 8, 24 | Gary W PaceDirector | SELL | 90.0K | $30.60 | $2.8M |
| Mar 7, 24 | Gary W PaceDirector | SELL | 28.3K | $30.81 | $871K |
| Mar 6, 24 | Gary W PaceDirector | SELL | 1.1K | $29.67 | $32K |
| Aug 2, 23 | Roy WinstonChief Medical Officer | SELL | 509 | $34.88 | $18K |
| Jul 5, 23 | Lauren Bullaro RikerSenior Vice President, Finance | SELL | 643 | $38.91 | $25K |
| Jun 14, 23 | Lauren Bullaro RikerSenior Vice President, Finance | SELL | 5.8K | $39.01 | $222K |
| Jun 14, 23 | Kristen Marie WilliamsChief Administrative Officer | SELL | 6.5K | $37.03 | $239K |
| Jun 8, 23 | Mark A. KronenfeldDirector | SELL | 15.0K | $37.04 | $556K |
| Jun 7, 23 | Ronald J. Ellis Jr.Chief Strategy Officer | SELL | 1.2K | $37.87 | $44K |
| Jun 7, 23 | Dennis McLoughlinChief Customer Officer | SELL | 1.1K | $37.87 | $40K |
| Jun 7, 23 | Max ReinhardtPresident, Rest of World | SELL | 1.1K | $37.87 | $42K |
| Jun 7, 23 | Charles A. Reinhart IIIChief Financial Officer | SELL | 1.4K | $37.87 | $52K |
| Jun 7, 23 | Lauren Bullaro RikerSenior Vice President, Finance | SELL | 616 | $37.87 | $23K |
| Jun 7, 23 | Jonathan SloninChief Clinical Officer | SELL | 490 | $37.87 | $19K |
| Jun 7, 23 | David M StackCEO and Chairman | SELL | 5.3K | $37.87 | $202K |
| Jun 7, 23 | Roy WinstonChief Medical Officer | SELL | 1.9K | $37.87 | $70K |
| Jun 7, 23 | Kristen Marie WilliamsChief Administrative Officer | SELL | 1.4K | $37.87 | $51K |
Over the past 12 months, insiders at Pacira BioSciences, Inc. filed 0 open-market purchases worth $0 and 15 sales worth $2.3M on PCRX, which makes them net sellers over the period. The most recent Form 4 was filed on Apr 23, 26.
The largest recent open-market PCRX insider purchase in our data was $100K by Frank D. Lee, Chief Executive Officer, filed on Aug 12, 24.
7 different insiders at Pacira BioSciences, Inc. filed open-market SEC Form 4 transactions on PCRX over the last 12 months.
InsiderTape plots every PCRX insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Pacira BioSciences, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →